Arizona GLP-1 Weight Loss Compliance 2026: Semaglutide, Tirzepatide & AZ Prescribing Rules

Two federal dates ended the compounded GLP-1 boom that built half the weight-loss programs in Arizona med spas: October 2, 2024, when the FDA removed tirzepatide from its drug shortage list, and February 21, 2025, when semaglutide came off as well.

Once a drug is off the shortage list, the federal "essentially-a-copy" rule kicks back in. Section 503A of the Food, Drug, and Cosmetic Act prohibits a state-licensed compounding pharmacy from compounding a drug that is essentially a copy of a commercially available FDA-approved product, except in narrow clinical circumstances. The shortage was the loophole. The shortage is gone.

For Arizona med spas, that change layers onto a state regulatory environment with two AZ-specific features that materially shape the GLP-1 picture: (1) full practice authority for nurse practitioners, which means a properly credentialed RNP can run a weight-loss program without a physician medical director, and (2) an active Arizona Medical Board that has been visibly enforcing overprescribing patterns since the GLP-1 boom began.

This guide covers what Arizona med spas can actually do in 2026 — what to prescribe, who can prescribe it, how to document it, where telehealth fits, and the AMB and AZ Board of Pharmacy patterns to avoid.

What Changed: The End of the Compounded GLP-1 Era

From roughly 2022 through mid-2024, FDA-approved GLP-1s were on the federal drug shortage list. That status had a specific consequence: compounding pharmacies could legally produce copies of semaglutide and tirzepatide for individual patients. Med spas across Phoenix, Scottsdale, Tucson, and the Valley built entire programs on this — sourcing compounded vials at $200–$400/month versus $900–$1,300/month retail for the branded products.

Tirzepatide — Off the List October 2, 2024

The FDA declared the tirzepatide shortage resolved on October 2, 2024, after Eli Lilly confirmed that supply of Mounjaro and Zepbound had stabilized. After a brief court-extended transition window, both 503A pharmacies and 503B outsourcing facilities lost the routine ability to compound tirzepatide copies for Arizona patients.

Semaglutide — Off the List February 21, 2025

Novo Nordisk reached supply normalization later. The FDA removed semaglutide from the shortage list on February 21, 2025. The transition for compounded semaglutide effectively ended in spring 2025, with the same outcome: 503A compounding of copies is no longer broadly permitted in Arizona or anywhere else.

The current FDA shortage status for any GLP-1 should be verified directly at the FDA Drug Shortages database before relying on a compounding-based protocol — both the federal essentially-a-copy rule and Arizona Board of Pharmacy enforcement turn on this status.

What's Still Allowed

Compounding hasn't disappeared entirely. Narrow paths remain:

• Documented clinical difference: A compounded formulation that is not "essentially a copy" — for example, a clinically necessary dose strength not available in the FDA-approved product, or an ingredient combination clinically indicated for a specific patient.
• Component allergy or intolerance: A documented patient-specific clinical need (such as an inactive-ingredient allergy or intolerance) supported in the chart.
• 503B outsourcing facilities: Limited compounding under stricter conditions, primarily for hospitals and clinics with documented need — not the routine commercial supply that fed med spa programs.

"My patient prefers the lower price" is not a clinical difference. "We always used compounded" is not a clinical difference. These rationales will not survive an Arizona State Board of Pharmacy audit or an AMB review.

What Arizona Med Spas Can Legally Prescribe in 2026

The Branded GLP-1 List

FDA-approved products that an Arizona-licensed prescriber can lawfully prescribe today:

• Semaglutide — Wegovy (weight loss indication), Ozempic (T2DM), Rybelsus (oral T2DM)
• Tirzepatide — Zepbound (weight loss), Mounjaro (T2DM)
• Liraglutide — Saxenda (weight loss), Victoza (T2DM)

Wegovy and Zepbound are the labeled-for-weight-loss options. Ozempic and Mounjaro are diabetes products that are sometimes prescribed off-label for weight management; off-label prescribing remains legal in Arizona when supported by a documented clinical rationale, but the chart must reflect that rationale.

Off-Label Prescribing in Arizona

Arizona does not prohibit off-label prescribing, but the standard of care still applies. If you prescribe Ozempic for a patient without diabetes, the chart needs to show why — BMI thresholds, comorbidities, prior weight-loss attempts, why a labeled product (Wegovy, Zepbound) wasn't used, and informed consent that addresses off-label use. Lack of this documentation is one of the most common findings in Arizona Medical Board weight-loss cases.

Who Can Prescribe GLP-1s at an Arizona Med Spa

Arizona's prescribing-authority rules apply across three license types. The provider must be:

• An Arizona-licensed allopathic physician (MD) under A.R.S. Title 32, Chapter 13 or osteopathic physician (DO) under Chapter 17, or
• An Arizona-licensed registered nurse practitioner (RNP) with prescriptive authority under A.R.S. §32-1601 et seq. — practicing independently under Arizona's full practice authority, or
• An Arizona-licensed physician assistant (PA) acting under physician supervision per the supervision agreement

Arizona's Full Practice Authority Advantage

This is the single most material AZ-specific point in the GLP-1 picture: Arizona is a full practice authority state for nurse practitioners. An RNP with prescriptive authority can independently evaluate, diagnose, prescribe, and own a med spa offering GLP-1 services without a collaborative agreement, written protocol, or physician oversight — provided the prescribing falls within the NP's certification population focus (FNP, AGNP, etc.).

That structural advantage is real, but it's not a documentation discount. The good-faith examination, contraindication screening, and chart standards described below apply to NP-prescribed GLP-1s identically to MD-prescribed GLP-1s. The AMB does not see RNP charts; the Arizona State Board of Nursing does, and AZBN reviews of overprescribing patterns mirror AMB reviews. For the deeper picture on NP scope and ownership, see our guide on Arizona NPs and full practice authority for med spas.

RNs cannot prescribe. They can administer GLP-1 injections under standing orders signed by an Arizona prescriber, but the prescribing decision — the good-faith examination, the medical necessity assessment, the chart entry — must come from a physician, NP, or PA. The same scope-of-practice line applies to other injectables — see who can inject Botox in Arizona for the broader rule.

The "Good Faith Examination" — What Arizona Requires

Arizona statute and Board guidance require a good-faith examination before a prescription is issued. The relevant provisions in A.R.S. §32-1854 (medical practice) and the analogous nursing rules treat prescribing without an adequate examination as unprofessional conduct. There is no statutory checklist, but enforcement actions tell a clear story.

Minimum Elements Documented

1. Patient history — current medications, allergies, prior weight-loss attempts, relevant surgical history, family history
2. Anthropometrics — verified height, weight, and BMI (a self-reported value alone is not adequate when the patient could be reasonably weighed)
3. Comorbidities — Type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease, prediabetes — these establish medical necessity
4. Contraindication screen — personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN-2), pancreatitis, severe gastrointestinal disease, gastroparesis, pregnancy or pregnancy planning, severe renal or hepatic impairment
5. Mental health screen — eating disorder history, suicidality (FDA labeling for GLP-1s notes psychiatric considerations)
6. Informed consent — risks, benefits, common adverse events (nausea, vomiting, constipation), serious risks (pancreatitis, gallbladder disease, MTC warning), pregnancy considerations, off-label use if applicable
7. Treatment plan — starting dose, titration schedule, follow-up intervals, monitoring plan, criteria for dose change or discontinuation

Recommended Pre-Treatment Labs

Not statutorily required for every patient, but standard of care for an Arizona GLP-1 weight-loss program — and what AMB and AZBN reviewers look for in a defensible chart:

• Hemoglobin A1c
• Comprehensive metabolic panel (kidney and liver function)
• Lipid panel
• TSH (thyroid function)
• Lipase (baseline if pancreatitis history is present)
• Pregnancy test for patients of childbearing potential

Telehealth Prescribing of GLP-1s in Arizona

Arizona permits the establishment of a practitioner-patient relationship via telehealth under A.R.S. §36-3601 et seq., the state's telehealth statutes. An in-person visit is not federally or state-required to issue a non-controlled prescription like a GLP-1, and Arizona expressly allows audio-video and, in limited cases, audio-only telehealth for established care.

However, telehealth does not lower the bar on the good-faith examination — it changes how the examination is conducted. The visit must still be a real clinical encounter, with synchronous audio-video where clinically appropriate.

Arizona Telehealth Requirements for GLP-1 Prescribing

• Synchronous interaction: Live audio-video for the initial visit. An online intake form alone is not sufficient under A.R.S. §36-3602.
• Provider identity verification: The patient must be able to verify the prescriber's identity, license, and credentials
• Patient location at time of service: The patient must be physically present in Arizona at the time of the encounter (or the provider must be licensed in the patient's state of presence)
• Informed telehealth consent: Specific consent for telehealth — separate from medical informed consent — including discussion of telehealth limitations and emergency procedures, as required under A.R.S. §36-3602(A)
• HIPAA-compliant platform: The video platform must support HIPAA, and Arizona's medical records access rules under A.R.S. §12-2293 apply to telehealth records
• Documented continuity: The chart must reflect a real practitioner-patient relationship — not a one-touch encounter

Out-of-State Telehealth Providers — A.R.S. §36-3606 Registration

Arizona offers a unique pathway for out-of-state telehealth practitioners through its telemedicine practitioner registration program under A.R.S. §36-3606. An otherwise-qualified out-of-state physician, NP, or PA can register with the appropriate Arizona regulatory board and deliver telehealth services to Arizona patients without obtaining a full Arizona license — subject to conditions including:

• No in-person practice in Arizona under the registration
• No prescribing of controlled substances under the registration
• Active, unrestricted license in the home state
• Annual registration renewal
• Compliance with Arizona's good-faith examination, telehealth consent, and recordkeeping rules

For GLP-1s specifically — non-controlled medications — the §36-3606 pathway is workable. Many national telehealth weight-loss platforms operate this way to reach Arizona patients without 50-state licensure. The structural compliance question for an Arizona med spa partnering with such a platform is whether the prescriber holds either an active Arizona license or a current §36-3606 registration.

The model that triggers AMB and AZBN complaints is the "5-minute intake" — a patient fills a web form, a clinician they never speak to issues a prescription, and a vial ships from out of state. That model is not a good-faith examination, and the AMB has issued discipline against physicians who structured their practice this way regardless of whether they used Arizona licensure or §36-3606 registration.

Pharmacy Partnership Rules in Arizona

The dispensing pharmacy is your second compliance surface. Arizona's pharmacy practice rules under A.R.S. Title 32, Chapter 18 set out prescription, dispensing, and compounding requirements. The Arizona State Board of Pharmacy oversees in-state pharmacies, registers non-resident (out-of-state) mail-order pharmacies that ship into AZ, and enforces the essentially-a-copy compounding restriction within Arizona.

In-State Dispensing Pharmacies

An Arizona-licensed retail or specialty pharmacy can dispense Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda directly to your patient on a valid Arizona prescription. Most large chains (CVS, Walgreens, Fry's, Safeway, Costco, independents) and weight-loss-focused specialty pharmacies meet this standard.

Out-of-State / Mail-Order Pharmacies

An out-of-state pharmacy can ship to Arizona patients only if it holds a current non-resident pharmacy permit issued by the Arizona State Board of Pharmacy. Before partnering, verify the registration:

• Confirm the permit in the AZ Board of Pharmacy license verification system
• Confirm the pharmacy carries the FDA-approved branded products and is not relying on compounded substitutions to undercut price
• Confirm the pharmacy's sterile compounding accreditations (USP <797>, <800>) if any sterile compounded product is in scope
• Get the permit number in writing for your file

Compounding Pharmacy Red Flags

If a pharmacy currently offers your Arizona med spa "compounded semaglutide" or "compounded tirzepatide" without a documented patient-specific clinical rationale, walk away. The legal exposure is on the prescriber as well as the pharmacy. An AZ Board of Pharmacy investigation can be triggered by an inspection or complaint, and the prescription record will lead directly back to your chart at the AMB or AZBN.

Refills, Follow-Up, and Continued Prescribing

Arizona does not specify a fixed follow-up interval for weight-loss prescribing, but standard of care drives the schedule:

• First follow-up: 4 weeks after initiation — assess tolerance, side effects, weight response, dose titration
• Subsequent follow-ups: Every 4–12 weeks during titration
• Maintenance: At least every 3 months once stable
• Annual labs: Repeat A1c, kidney/liver function, lipid panel
• Discontinuation criteria: Documented in the plan — stop if weight loss less than 5% at 12 weeks at maintenance dose, intolerable side effects, contraindication develops, or pregnancy

Auto-refilling a GLP-1 for 12+ months without a follow-up encounter is a structural red flag in any AMB or AZBN review. Build a recall workflow before you write the first prescription.

Arizona Medical Board Overprescribing Patterns

The Arizona Medical Board enforces medical practice misconduct under A.R.S. §32-1854. The patterns that have produced GLP-1-related discipline in Arizona — and parallel patterns from the AZ State Board of Nursing for NP-prescribed cases:

Pattern 1: Form-Driven Prescribing

The patient fills out a web form. A reviewing clinician checks boxes and signs off. There is no synchronous encounter. The chart is essentially the form. AMB has treated this as failure to conduct a good-faith examination under §32-1854.

Pattern 2: Unsigned Standing Orders

A protocol document allows medical assistants or RNs to "approve" weight-loss intakes without a prescribing clinician's individualized review. Standing orders can authorize administration of an already-prescribed medication. They cannot authorize the prescribing decision in Arizona.

Pattern 3: Missing Contraindication Screening

Charts that do not document the MTC/MEN-2 family-history screen, pancreatitis screen, or pregnancy screen. The black-box warning on GLP-1 labeling exists for a reason; charts that ignore it are easy targets in a Board review.

Pattern 4: NP Population-of-Focus Mismatch

An RNP whose national certification is in a non-adult population (PNP, neonatal) prescribing weight-loss medications to adult patients. Population-of-focus mismatch is an independent disciplinary finding by the AZBN regardless of the prescription's clinical merit, and Arizona's full practice authority does not waive certification scope.

Pattern 5: Missing Telehealth Consent

The chart contains a generic medical consent but no separate telehealth-specific consent under A.R.S. §36-3602. Arizona treats telehealth consent as a distinct disclosure obligation.

How Arizona Compares to Federal GLP-1 Standards

Most of what Arizona requires also tracks federal best practice. For the federal-level picture and how it applies across states, see our national GLP-1 weight-loss compliance guide. AZ-specific layers on top:

• Full practice authority for NPs — RNPs can independently run weight-loss programs without a collaborative agreement
• The §36-3606 telemedicine practitioner registration creates a pathway for out-of-state providers without full AZ licensure
• AZ Board of Pharmacy actively enforces non-resident permit requirements for out-of-state mail-order pharmacies
• The good-faith examination doctrine under §32-1854 is enforced by both AMB and AZBN
• Telehealth consent under §36-3602 is treated as a discrete obligation

The Operational Checklist

If you operate an Arizona med spa offering GLP-1s, this is the minimum operational stack you should be able to produce on demand:

1. Written GLP-1 SOP signed by the medical director or, in an RNP-owned practice, by the supervising RNP, covering eligibility, contraindications, dose titration, monitoring, and discontinuation
2. Patient assessment template with all good-faith examination elements
3. Contraindication screening checklist (MTC/MEN-2, pancreatitis, pregnancy, gastroparesis, etc.)
4. Informed consent form covering risks, benefits, off-label use, pregnancy
5. Telehealth informed consent separate from medical consent, compliant with A.R.S. §36-3602
6. HIPAA-compliant telehealth platform with synchronous audio-video
7. Pharmacy partnership documentation — copy of AZ pharmacy permit or non-resident pharmacy permit number
8. Follow-up workflow with scheduled recalls at 4 weeks, then 4–12 weeks during titration
9. Discontinuation criteria documented in the SOP
10. Adverse event log tracking nausea/GI events, suspected pancreatitis, gallbladder events
11. §36-3606 telemedicine registration documentation if any provider operates under that pathway

For the broader Arizona compliance picture across all procedures, see the Arizona med spa compliance checklist, the AZ medical director requirements, and the AZ advertising rules guide.

What Doesn't Apply: Controlled Substance Frameworks

For clarity: GLP-1 receptor agonists are not controlled substances. They are not subject to:

• Arizona Controlled Substances Prescription Monitoring Program reporting
• EPCS (Electronic Prescribing of Controlled Substances) mandates
• DEA registration for the prescriber (a DEA number is needed only if the practice prescribes any controlled substance)

Electronic prescribing for GLP-1s is best practice for legibility, audit, and pharmacy efficiency, but is not legally mandated. If your practice also offers other weight-management drugs that are controlled (phentermine, for example, is a Schedule IV controlled substance), those are subject to Arizona's CSPMP and related EPCS rules — and that's a separate workflow that does require DEA registration and §36-3606 limitations for out-of-state telehealth providers.

Summary

1. The FDA removed tirzepatide (October 2024) and semaglutide (February 2025) from its drug shortage list — routine 503A compounded GLP-1s are no longer broadly legal in Arizona
2. Arizona med spas should prescribe FDA-approved branded GLP-1s: Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda
3. Arizona's full practice authority lets a properly credentialed RNP independently prescribe GLP-1s and own a med spa without physician oversight — a meaningful AZ-specific structural advantage
4. A "good faith examination" is required before prescribing — BMI, comorbidities, contraindications, informed consent, treatment plan
5. Telehealth prescribing is permitted under A.R.S. §36-3601 et seq., but a synchronous audio-video encounter and separate telehealth consent under §36-3602 are required
6. Out-of-state pharmacies must hold an Arizona non-resident pharmacy permit; out-of-state telehealth providers can use the §36-3606 registration pathway for non-controlled prescribing
7. The Arizona Medical Board and AZ State Board of Nursing have disciplined providers for form-driven prescribing, missing contraindication screens, and population-mismatch NP prescribing

Disclaimer: This article is for educational purposes only and does not constitute legal or medical advice. GLP-1 prescribing involves federal and state regulatory considerations that change frequently. Verify current FDA shortage status and consult with an Arizona healthcare attorney and your medical director (or, in an RNP-owned practice, your collaborating attorney) before establishing or modifying a weight-loss program.